Doctors within MD Anderson’s Children’s Cancer Hospital have embarked on a unified effort to improve treatment options for pediatric patients with osteosarcoma (bone) and rhabdomyosarcoma (muscle groups). The five-year survival rate has stagnated over the last 25 years — somewhere between 65-70 percent. Once the cancer metastasizes to the lungs, that number drops to 30 percent. We are now looking to test the effectiveness of NK cells as they interact with other immuno-building blocks.
With the immediate goal of improving survival rates for pediatric osteosarcoma and rhabdomyosarcoma, and eventually applying that knowledge to establish a cure against all sarcomas, our team of pediatric oncologists and basic science collaborators is poised for Making Cancer History.